Overall, CCR10–CCL27/CCL28 interactions facilitate Th22 cell migration and activation, contributing to inflammation and positioning this axis as a potential therapeutic target in cancer and other inflammatory diseases (76, 78–80). This evidence concerns the gene CCR10 and cancer.